Factors | Initial Effect | Expected 1yr Recovery | Comments |
---|---|---|---|
Company Sales/Revenue | Strong | Moderate | Many dental companies have forecasted strong revenue loss over 1 to 1.5 quarters (depending on the region) in 2020. |
Procedure Volumes | Strong | Moderate | Most dental markets are elective and physician associations/regulatory bodies have asked physicians to postpone elective procedures; however, as earlier restrictions are now easing in a number of countries (or certain states, provinces, and cities), some procedures will be resumed Travel restrictions will impact medical tourism significantly |
ASP | Moderate | Moderate | Companies in this space are offering discounted pricing on various dental products to support the reopening of dental practices and to encourage device purchases |
New Product Launches | Moderate | Moderate | Delays have been observed in the launch of some products in China in Q1 and in the US and Europe in Q2 2020. Implementation of the EU MDR is postponed by one year |
Clinical Trials | Strong | Moderate | Monitoring will continue in most clinical trials through phone or video consultations; however, new treatment will be limited/postponed, affecting analysis and timelines |
Supply Chain | Weak | Strong | Little disruption is being seen in the supply chain, especially for MNCs, and because of low manufacturing complexity. In cases of disruptions, recovery within 1.5 quarters is expected |